Introduction
============

Tuberculosis (TB) remains a global public health threat, especially in developing countries.[@b1-idr-11-323] Although TB control has been effective in some regions of the world, the emergence of multidrug-resistant (MDR) and extensively drug-resistant TB during the past decade threatens to undermine these advances.[@b2-idr-11-323],[@b3-idr-11-323]

Molecular epidemiology is increasingly used as a complementary tool to conventional epidemiology.[@b4-idr-11-323] Genotyping of *Mycobacterium tuberculosis* (*Mtb*) has been used to enhance our understanding of the TB epidemic and determine the routes of transmission. Cases with indistinguishable molecular characteristics of strains more likely contribute to recent transmission, whereas cases caused by strains with unique fingerprints are typically due to the reactivation of latent infection.[@b5-idr-11-323] Restriction fragment length polymorphism (RFLP) targeting the insertion sequence *6110* (IS*6110*) transposable element has been widely used and considered as a gold standard tool. However, this method requires large amounts of high-quality DNA and has poor discriminatory power for isolates with \>6 copies of IS*6110*.[@b6-idr-11-323] Other alternative molecular tools include mixed linker PCR (ML-PCR), double-repetitive-element PCR (DRE-PCR), fast ligation-mediated PCR (FliP), spacer oligonucleotide typing (spoligotyping), and mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) typing, among others.[@b4-idr-11-323],[@b6-idr-11-323]

TB is highly prevalent in China, and studies on the mode of transmission have been carried out in some regions; however, few efforts in fingerprinting analysis have been made based on the mutation profiles of isolates from the east region.[@b7-idr-11-323]--[@b10-idr-11-323] Jiangsu is located in the east part of China, absorbs a large number of migrations and has the highest population density in China.[@b11-idr-11-323] Exploring the pattern of *Mtb* transmission and drug resistance in this area could substantially facilitate local and countrywide TB control. The objectives of the present study were to characterize and classify the clinical isolates prevailing in the northeast of Jiangsu and to investigate the mode of transmission. The study also aimed to explore the extent to which *Mtb* strains contributed to drug resistance and the possible factors related to the recent spread of TB strains.

Patients and methods
====================

Study setting and participants
------------------------------

This study was conducted in Lianyungang City, which is located in the center of China's vast ocean area, the northeast of Jiangsu province and the extreme north of the Yangtze River Delta. We have consecutively enrolled 912 culture-confirmed TB cases from 1 January 2013 to 31 December 2014. The Institutional Review Board of Nanjing Medical University approved this study. Written informed consent was obtained from all participants included in the study.

Data collection
---------------

Sputum samples from each TB suspect were collected for acid-fast bacilli (AFB) smear microscopy, which was performed at local hospitals. All AFB smear-positive samples were routinely transported to the Fourth People's Hospital of Lianyungang for culture and drug susceptibility testing (DST). Drug resistance to rifampicin (RIF), isoniazid (INH), ofloxacin (OFLX), and kanamycin (KA) was assessed based on the proportion method as recommended by WHO/IUATLD (International Union against Tuberculosis and Lung Disease). Genomic DNA was obtained by suspending mycobacterial colonies in 100--200 μl distilled H~2~O and incubating at 85°C for 30 min. All isolates were genotyped using 15-locus MIRU-VNTR typing (Mtub04, ETRC, ETRD, MIRU40, MIRU10, MIRU16, Mtub21, Qub11b, ETRA, Mtub30, MIRU26, ETRE, Mtub39, Qub26, and Qub4156). The primers used to amplify specific loci are described in [Table 1](#t1-idr-11-323){ref-type="table"}. PCR was performed on an amplifier (MJ Research, Inc., Watertown, MA, USA), and the amplification products were separated by agarose gel electrophoresis. The product sizes were estimated by comparison with the 50 bp and 100 bp ladder markers. The copy number per locus was calculated using the method described by Supply et al.[@b12-idr-11-323] We applied the "pheatmap" package of R software to perform the clustering analysis.[@b13-idr-11-323]

Data analysis
-------------

Data were entered and analyzed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). Characteristics of cases with different strains were compared using the *χ*^2^ or Fisher's exact test. A multivariate logistic regression model was applied to estimate the effect of factors related to drug resistance, clustering, and cluster size. The test level was set at 0.05. A cluster was defined as two or more isolates from different patients with identical MIRU patterns, whereas nonclustered patterns were referred to as unique. If the cluster contained five or more cases, it was defined as a large cluster. The index case in each large cluster was temporally defined as the first case diagnosed within the cluster. The rate of recent transmission was calculated by the formula: \[Tc--Nc\]/Ta\*100%, where Tc was the total number of clustered isolates, Nc was the number of clusters, and Ta was the total number of isolates. The "pheatmap" package of R software was used to plot the MIRU--VNTR results. The dendrograms based on 15 VNTR locus data were conducted using the unweighted pair group method with arithmetic mean protocol. According to the first-class clustering results, the samples were divided into MIRU-type I and II. The Hunter--Gaston discrimination index (HGDI) for the loci in MIRU-15 sets was used to estimate the discriminatory power of the genotyping method and the diversity of molecular markers.[@b14-idr-11-323],[@b15-idr-11-323] $HGDI = 1\frac{1}{N(N - 1)}{\sum\limits_{j = 1}^{s}{n_{j}(n_{j} - 1)}},\quad\text{where}\ N\ \text{is}\ \text{the}\ \text{total}$ number of strains, n~j~ is the number of strains of the j genotype, and s is the MIRU-VNTR locus genotype number.

Results
=======

We genotyped 912 clinical samples, and 741 (81.25%) isolates provided complete data for the entire MIRU-15 set. Among the 741 TB patients, 135 (18.22%) were previously treated, 274 (36.98%) were aged over 60 years, and 587 (79.22%) were male. DST showed that the drug resistance to RIF, INH, OFLX, and KA was 8.37%, 11.74%, 9.04% and 0.68%, respectively. The proportion of MDR-TB was 5.94%, which was higher among patients aged \<60 years ([Table 2](#t2-idr-11-323){ref-type="table"}).

According to the genotypes of the MIRU-15 loci, strains were categorized into different groups. The total HGDI for all loci was 0.999 ([Table 1](#t1-idr-11-323){ref-type="table"}). The estimated proportion of recent transmission was 13.34%. As shown in [Figure 1](#f1-idr-11-323){ref-type="fig"}, two main groups were categorized, and we defined them as MIRU-type I (n=214, 28.88%) and MIRU-type II (n=527, 71.12%). The ETRE, MIRU10, MTUB04, MIRU40, Mtub21, Mtub30, Mtub39, and MIRU26 loci had more repeated sequences in the MIRU-type II group than in the MIRU-type I group. The MIRU-type I and II classification was significantly associated with gender (*χ*^2^=6.21, *P*=0.013), age (*χ^2^*=4.67, *P*=0.031), and clustering (*χ^2^*=53.15, *P*\<0.001) ([Table 3](#t3-idr-11-323){ref-type="table"}).

One hundred forty-four (19.43%) strains formed 46 clusters, while 597 (80.57%) isolates had a unique MIRU pattern ([Figure 1](#f1-idr-11-323){ref-type="fig"}). The average cluster size was 3 (2--13) cases. Over 38.19% of clusters contained two cases, and the largest cluster included 13 cases. We have plotted patients in a geographic information system map. There were 9 patients in cluster 1, which was mainly distributed in the north part of Lianyungang. Cluster 2 included 5 patients, all living in the south part of the study area. There were 5 patients in cluster 3, and they were distributed throughout the whole city. Cluster 4 included 12 patients, mainly distributed in the east or south area ([Figure 2](#f2-idr-11-323){ref-type="fig"}). We have further categorized 144 clustered strains into two groups: small clusters (including 2--4 cases) and large clusters (including 5 or more cases). No significant factors were observed to be related with cluster size ([Table 4](#t4-idr-11-323){ref-type="table"}).

As shown in [Table 5](#t5-idr-11-323){ref-type="table"}, strains in the MIRU-type II group were more likely to form a cluster (adjusted OR: 13.25, 95% CI: 5.73--30.62, *P*\<0.001). Patients with unfavorable treatment outcomes were infected with clustered strains at a higher proportion than were those with favorable treatment outcomes (adjusted OR:1.78, 95% CI: 1.14--2.85, *P*=0.012).

Discussion
==========

We have consecutively enrolled TB cases from one region of China and genotyped them using the 15-locus MIRU-VNTR. The proportion of clustering in the study area was 19.43%, and the recent transmission rate was 13.34%, which was lower than that reported in some developed countries. For example, a study conducted in London reported that 46% were clustered and the estimated proportion attributable to recent transmission was 34%.[@b16-idr-11-323] Another study performed in the UK reported that the proportion of cases attributable to recent transmission was 15%.[@b17-idr-11-323] In the Netherlands, 46% of strains were found in clusters with identical RFLPs, and 35% were attributed to active transmission.[@b18-idr-11-323] In the United States, recent transmission was estimated to be 48% from 1996 to 2000 but decreased to 23% in 2005--2009.[@b19-idr-11-323],[@b20-idr-11-323] The proportion of recent transmission was relatively low in our study, indicating the higher possibility of recrudescence in the study area. This may partly contribute to the higher prevalence of latent infection in the Chinese population.[@b21-idr-11-323] In 2013, a population-based study conducted in rural China reported that the age-standardized and sex-standardized rates of skin-test positivity (≥10 mm) ranged from 15% to 42%, and the QuantiFERON positivity rates ranged from 13% to 20%.[@b22-idr-11-323] Another cross-sectional study that was undertaken in eastern of China reported that the positive rate of the interferon-gamma release assay was 19.98%.

According to the genotypes of MIRU-15 loci, two main groups were categorized (MIRU-type I and II). The classification was significantly associated with gender and age. This finding might be explained as different recent transmission rates among specific populations. Previous studies have reported that recent TB infection is associated with a variety of factors, including youth, male sex, belonging to an ethnic minority, homelessness, drug use, excessive alcohol consumption, homelessness, and previous incarceration.[@b23-idr-11-323] Factors related to clustering varied greatly between areas. In a UK study conducted by Hamblion et al, the clustered patients were more likely to be born in the UK, to have been diagnosed with pulmonary TB, to have a previous TB history, to have issues with substance abuse or alcohol abuse, and to have been imprisoned.[@b16-idr-11-323] Another UK study conducted by Anderson et al found that being born in the UK and using illicit drugs were significantly associated with clustering.[@b17-idr-11-323] Using the 15-locus MIRU method, a study in Jiangxi province, China, reported that patients who failed treatment or patients with MDR isolates were more likely to be in clusters.[@b24-idr-11-323] In our study, we observed that clustered cases were more likely to have a unfavorable treatment outcome. With the extension of sputum bacteriological conversion, the risk of ongoing transmission among the community also increased. Compared with that in other studies, the size of clustered cases was small in the current study, which may result in a relatively small sample size over a short time period.

Strain genotyping data, when combined with epidemiological data, enabled the identification of TB patients involved in the same chain of transmission. We assume that cases sharing the same strain (in the same cluster) were recently infected in Lianyungang. We have plotted cases forming large clusters on the map. Cases in cluster 1 or 2 mainly lived together in a small area. We hypothesized that the strains were probably transmitted through the same source of infection.[@b25-idr-11-323] The MIRU-VNTR loci and drug resistance have been explored in previous studies. For example, the ETRB locus was associated with INH resistance,[@b26-idr-11-323] and the MIRU20 locus was associated with EMB resistance.[@b27-idr-11-323],[@b28-idr-11-323]

In 1997, Supply et al identified a novel minisatellite-like structure in the *Mtb* genome and named such structures MIRUs.[@b29-idr-11-323] These MIRUs are located mainly in intergenic regions and are dispersed throughout the *Mtb* genome. In 2001, Supply et al proved the usefulness of MIRUs for epidemiologic study by conducting PCR analysis of 12 variable tandem repeat loci with specific primers followed by gel electrophoresis.[@b12-idr-11-323] Supply et al proposed a 15-locus system as a new standard for routine epidemiological discrimination of *Mtb* isolates and a 24-locus system as a high-resolution tool for phylogenetic studies.[@b30-idr-11-323] Although several optimal loci have been suggested for genotyping homogenous *Mtb*,[@b16-idr-11-323],[@b31-idr-11-323],[@b32-idr-11-323] 15 loci have been widely used in China.[@b33-idr-11-323]--[@b35-idr-11-323] In the current study, the total HGDI for all 15 loci was 0.999. The locus Qub11b had the highest HGDI (0.762), while the HGDI of ETRC was very low (0.036). Identical MIRU-VNTR patterns are considered to be in a cluster. It was reported that the proportion of clustering decreased with a greater number of MIRU-VNTR loci typed, with increasing TB incidence and with increasing maximum cluster size.[@b36-idr-11-323]

Limitations
===========

Our study has some limitations. First, samples were collected over a relatively short time period. The probability of clustering might be underestimated. A long-term cohort study can solve this problem. Second, China has a high proportion of the Beijing lineage of *Mtb*. In this study, we did not analyze the lineage of the Beijing family. Third, epidemiological data are essential for identifying the route of transmission. In this study, we lack necessary information such as the history of contact with the patients or the frequency of visiting areas with high population density. Thus, we could not clearly explain the chain of transmission for patients in the same cluster.

Conclusion
==========

The probability of recent TB transmission was relatively low in the study site, and the cases mainly came from the activation of previous infection. Spatial analysis showed that some strains in the larger clusters had the characteristics of regional aggregation.
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![Dendrogram of 741 *Mtb* isolates from Lianyungang, China.\
**Note:** The phylogenetic tree was generated from the 15-locus MIRU-VNTR profile: ETRA -- ETRC -- ETRD -- ETRE -- MIRU10 -- MIRU16 -- MIRU26 -- MIRU40 -- MTUB04 -- MTUB21 -- MTUB30 -- MTUB39 -- Qub11b -- Qub4156 -- Qub26. Changes in strip color from dark blue to orange correspond to increasing numbers of repeats, from 0 to 12.\
**Abbreviations:** MIRU, mycobacterial interspersed repetitive unit; VNTR, variable number tandem repeat.](idr-11-323Fig1){#f1-idr-11-323}

![Distribution of large clustered strains.\
**Notes:** Circle with date indicates the index case. The red boxes indicate that cluster 1 strains are located in the north part while cluster 3 strains are located in the south part.\
**Abbreviation:** GIS, geographic information system.](idr-11-323Fig2){#f2-idr-11-323}

###### 

Primers and HGDI for the 15 MIRU-VNTR loci

  Loci                        Sequence (5′→3′)               HGDI
  --------------------------- ------------------------------ -------
  Mtub04                      CTTGGCCGGCATCAAGCGCATTATT      0.511
  GGCAGCAGAGCCCGGGATTCTTC                                    
  ETRC                        CGAGAGTGGCAGTGGCGGTTATCT       0.036
  AATGACTTGAACGCGCAAATTGTGA                                  
  ETRD                        GCGCGAGAGCCCGAACTGC            0.344
  GCGCAGCAGAAACG**C**CAGC                                    
  MIRU40                      GGGTTGCTGGATGACAACGTGT         0.509
  GGGTGATCTCGGCGAAATCAGATA                                   
  MIRU10                      GTTCTTGACCAACTGAGTCGTCC        0.624
  GCCACCTTGGTGATCAGCTACCT                                    
  MIRU16                      TCGGTGATCGGGTCCAGTCCAAGTA      0.231
  CCCGTCGTGCAGCCCTGGTAC                                      
  Mtub21                      AGATCCCAGTTGTCGTCGTC           0.747
  CAACATCGCCTGGTTCTGTA                                       
  Qub11b                      CGTAAGGGGGATGCGGGAAATAGG       0.762
  CGAAGTGAATGGTGGCAT                                         
  ETRA                        AAATCGGTCCCATCACCTTCTTAT       0.397
  CGAAGCCTGGGGTGCCCGCGATTT                                   
  Mtub30                      CTTGAAGCCCCGGTCTCATCTGT        0.382
  ACTTGAACCCCCACGCCCATTAGTA                                  
  MIRU26                      TAGGTCTACCGTCGAAATCTGTGAC      0.727
  CATAGGCGACCAGGCGAATAG                                      
  ETRE                        ACTGATTGGCTTCATACGGCTTTA       0.597
  GTGCCGACGTGGTCTTGAT                                        
  Mtub39                      CGGTGGAGGCGATGAACGTCTTC        0.428
  TAGAGCGGCACGGGGGAAAGCTTAG                                  
  Qub26                       CGGCCGTGCCGGCCAGGTCCTTCCCGAT   0.610
  AACGCTCAGCTGTCGGAT                                         
  Qub4156                     TGGTCGCTACGCATCGTGTCGGCCCGT    0.242
  TACCACCCGGGCAGTTTAC                                        
  Total                       --                             0.999

**Abbreviations:** HGDI: Hunter--Gaston discrimination index; MIRU, mycobacterial interspersed repetitive unit; VNTR, variable number tandem repeat.

###### 

Resistance to antituberculosis drugs stratified by age groups

  Drug resistance      All cases, N (%)   Age group, N (%)   *χ*^2^        *P*     
  -------------------- ------------------ ------------------ ------------- ------- ---------
  Resistance to RIF                                                                
   No                  679 (91.63)        415 (88.87)        264 (96.35)   16.62   \<0.001
   Yes                 62 (8.37)          52 (11.13)         10 (3.65)             
  Resistance to INH                                                                
   No                  654 (88.26)        407 (87.15)        247 (90.15)   1.49    0.222
   Yes                 87 (11.74)         60 (12.85)         27 (9.85)             
  Resistance to OFLX                                                               
   No                  674 (90.96)        428 (91.65)        246 (89.78)   0.73    0.392
   Yes                 67 (9.04)          39 (8.35)          28 (10.22)            
  Resistance to KA                                                                 
   No                  736 (99.32)        465 (99.57)        271 (98.91)   1.14    0.285
   Yes                 5 (0.68)           2 (0.43)           3 (1.09)              
  DR-TB                                                                            
   No                  598 (80.70)        374 (80.09)        224 (81.75)   0.31    0.579
   Yes                 143 (19.30)        93 (19.91)         50 (18.25)            
  MDR-TB                                                                           
   No                  697 (94.06)        431 (92.29)        266 (97.08)   7.09    0.008
   Yes                 44 (5.94)          36 (7.71)          8 (2.92)              

**Notes:** DR-TB: drug resistance to RIF, INH, OFLX or KA; MDR-TB: drug resistance to RIF and INH.

**Abbreviations:** RIF, rifampicin; INH, isoniazid; OFLX, ofloxacin; KA, kanamycin; DR, drug-resistance; TB, tuberculosis; MDR, multidrug-resistant.

###### 

Characteristics of strains genotyped in Lianyungang

  Variables                                                     All, N (%)    MIRU-type I, N (%)   MIRU-type II, N (%)   *χ*^2^   *P*
  ------------------------------------------------------------- ------------- -------------------- --------------------- -------- ---------
  Gender                                                                                                                          
   Male                                                         587 (79.22)   182 (85.05)          405 (76.85)           6.21     0.013
   Female                                                       154 (20.78)   32 (14.95)           122 (23.15)                    
  Age (years)                                                                                                                     
   \<60                                                         467 (63.02)   122 (57.00)          345 (65.50)           4.67     0.031
   ≥60                                                          274 (36.98)   92 (43.00)           182 (34.50)                    
  TB history                                                                                                                      
   New cases                                                    606 (81.78)   180 (84.11)          426 (80.83)           1.10     0.295
   Previously treated                                           135 (18.22)   34 (15.89)           101 (19.17)                    
  Location                                                                                                                        
   Urban                                                        207 (27.79)   50 (23.36)           157 (29.79)           3.12     0.077
   Rural                                                        534 (72.21)   164 (76.64)          370 (70.21)                    
  Clustering                                                                                                                      
   Unique                                                       597 (80.57)   208 (97.20)          389 (73.81)           53.15    \<0.001
   Clustered                                                    144 (19.43)   6 (2.80)             138 (26.19)                    
  Treatment outcome[a](#tfn4-idr-11-323){ref-type="table-fn"}                                                                     
   Successful                                                   507 (84.78)   158 (87.78)          349 (83.49)           1.79     0.181
   Unsuccessful                                                 91 (15.22)    22 (12.22)           69 (16.51)                     

**Note:**

With missing values.

**Abbreviations:** MIRU, mycobacterial interspersed repetitive unit; TB, tuberculosis.

###### 

Factors related to cluster size

  Variables                                                     Size of cluster, N (%)   OR           95% CI   *P*          aOR[a](#tfn6-idr-11-323){ref-type="table-fn"}   95% CI[a](#tfn6-idr-11-323){ref-type="table-fn"}   *P*          
  ------------------------------------------------------------- ------------------------ ------------ -------- ------------ ----------------------------------------------- -------------------------------------------------- ------------ -------
  Gender                                                                                                                                                                                                                                    
   Male                                                         80 (84.21)               42 (85.71)   1                                                                     1                                                               
   Female                                                       15 (15.79)               7 (14.29)    0.89     0.34--2.35   0.812                                           0.91                                               0.34--2.41   0.845
  Age (years)                                                                                                                                                                                                                               
   \<60                                                         60 (63.16)               28 (57.14)   1                                                                     1                                                               
   ≥60                                                          35 (36.84)               21 (42.86)   1.29     0.64--2.60   0.483                                           1.28                                               0.63--2.59   0.492
  Location                                                                                                                                                                                                                                  
   Urban                                                        30 (31.58)               10 (20.41)   1                                                                     1                                                               
   Rural                                                        65 (68.42)               39 (79.59)   0.56     0.25--1.26   0.159                                           0.57                                               0.25--1.31   0.188
  TB history                                                                                                                                                                                                                                
   New cases                                                    80 (84.21)               34 (69.39)   1                                                                     1                                                               
   Previously treated                                           15 (15.79)               15 (30.61)   2.35     1.04--5.35   0.041                                           2.30                                               1.00--5.30   0.050
  DR-TB                                                                                                                                                                                                                                     
   No                                                           80 (84.21)               42 (85.71)   1                                                                     1                                                               
   Yes                                                          15 (15.79)               7 (14.29)    0.90     0.34--2.35   0.812                                           0.90                                               0.34--2.39   0.833
  MDR-TB                                                                                                                                                                                                                                    
   No                                                           91 (95.79)               46 (93.88)   1                                                                     1                                                               
   Yes                                                          4 (4.21)                 3 (6.12)     1.50     0.32--6.91   0.615                                           1.53                                               0.34--7.15   0.591
  Treatment outcome[b](#tfn7-idr-11-323){ref-type="table-fn"}                                                                                                                                                                               
   Successful                                                   71 (87.65)               31 (77.50)   1                                                                     1                                                               
   Unsuccessful                                                 10 (12.35)               9 (22.50)    2.06     0.76--5.57   0.154                                           2.04                                               0.75--5.53   0.160

**Notes:**

Adjusted for age and gender;

with missing values; DR-TB: drug resistance to RIF, INH, OFLX or KA; MDR-TB: drug resistance to RIF and INH.

**Abbreviations:** TB, tuberculosis; DR, drug-resistance; MDR, multidrug-resistant; MIRU, mycobacterial interspersed repetitive unit; RIF, rifampicin; INH, isoniazid; OFLX, ofloxacin; KA, kanamycin.

###### 

Factors related to the clustering of strains

  Variables                                                      Clustered, N (%)   OR            95% CI   *P*           aOR[a](#tfn9-idr-11-323){ref-type="table-fn"}   95% CI[a](#tfn9-idr-11-323){ref-type="table-fn"}   *P*[a](#tfn9-idr-11-323){ref-type="table-fn"}   
  -------------------------------------------------------------- ------------------ ------------- -------- ------------- ----------------------------------------------- -------------------------------------------------- ----------------------------------------------- ---------
  Gender                                                                                                                                                                                                                                                                    
   Male                                                          465 (77.89)        122 (84.72)   1                                                                      1                                                                                                  
   Female                                                        132 (22.11)        22 (15.28)    0.64     0.39--1.04    0.071                                           0.64                                               0.39--1.05                                      0.079
  Age (years)                                                                                                                                                                                                                                                               
   \<60                                                          379 (63.48)        88 (61.11)    1                                                                      1                                                                                                  
   ≥60                                                           218 (36.52)        56 (38.89)    1.11     0.76--1.61    0.597                                           0.94                                               0.65--1.37                                      0.750
  TB history                                                                                                                                                                                                                                                                
   New cases                                                     492 (82.41)        114 (79.17)   1                                                                      1                                                                                                  
   Previously treated                                            105 (17.59)        30 (20.83)    1.23     0.78--1.94    0.366                                           1.19                                               0.75--1.88                                      0.463
  Location                                                                                                                                                                                                                                                                  
   Urban areas                                                   167 (28.00)        40 (27.78)    1                                                                      1                                                                                                  
   Rural areas                                                   430 (72.00)        104 (72.22)   0.99     0.66--1.52    0.963                                           1.03                                               0.65--1.53                                      0.906
  DR-TB                                                                                                                                                                                                                                                                     
   No                                                            476 (79.73)        122 (84.72)   1                                                                      1                                                                                                  
   Yes                                                           121 (20.27)        22 (15.28)    0.71     0.43--1.17    0.18                                            0.72                                               0.44--1.18                                      0.186
  MDR-TB                                                                                                                                                                                                                                                                    
   No                                                            560 (93.80)        137 (95.14)   1                                                                      1                                                                                                  
   Yes                                                           37 (6.20)          7 (4.86)      0.77     0.34--1.77    0.543                                           0.80                                               0.35--1.83                                      0.589
  MIRU type                                                                                                                                                                                                                                                                 
   I                                                             208 (34.84)        6 (4.17)      1                                                                      1                                                                                                  
   II                                                            389 (65.16)        138 (95.83)   12.30    5.34--28.33   \<0.001                                         13.25                                              5.73--30.62                                     \<0.001
  Treatment outcome[b](#tfn10-idr-11-323){ref-type="table-fn"}                                                                                                                                                                                                              
   Successful                                                    374(77.92)         82(67.77)     1                                                                      1                                                                                                  
   Unsuccessful                                                  106(22.08)         39(32.23)     1.68     1.08--2.56    0.021                                           1.78                                               1.14--2.85                                      0.012

**Notes:**

Adjusted for age and gender;

with missing values; DR-TB: drug resistance to RIF, INH, OFLX or KA; MDR-TB: drug resistance to RIF and INH.

**Abbreviations:** TB, tuberculosis; DR, drug-resistance; MDR, multidrug-resistant, RIF, rifampicin; INH, isoniazid; OFLX, ofloxacin; KA, kanamycin.
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